{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:34:05Z","timestamp":1792672445455,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.vaccine.2014.06.058","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T20:45:17Z","timestamp":1403383517000},"page":"4644-4650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice"],"prefix":"10.1016","volume":"32","author":[{"given":"Penelope","family":"Koraka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend-Jan","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Chubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert van","family":"Amerongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"L\u00f6vgren-Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byron E.E.","family":"Martina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouke","family":"Roose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.M.","family":"Rottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.06.058_bib0005","first-page":"1","article-title":"WHO expert consultation on rabies","volume":"931","author":"WHO","year":"2005","journal-title":"World Health Organ Tech Rep Ser"},{"issue":"44","key":"10.1016\/j.vaccine.2014.06.058_bib0010","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1016\/j.vaccine.2010.08.082","article-title":"Rabies vaccines: WHO position paper\u2014recommendations","volume":"28","author":"WHO","year":"2010","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2014.06.058_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2012.04592.x","article-title":"Developments in rabies vaccines","volume":"169","author":"Hicks","year":"2012","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.06.058_bib0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/0042-6822(92)90465-2","article-title":"Rabies virus glycoprotein is a trimer","volume":"187","author":"Gaudin","year":"1992","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2014.06.058_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbiotec.2005.06.009","article-title":"High level expression of surface glycoprotein of rabies virus in tobacco leaves and its immunoprotective activity in mice","volume":"119","author":"Ashraf","year":"2005","journal-title":"J Biotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2014.06.058_bib0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/14760584.2.3.399","article-title":"New approaches to the prevention and eradication of rabies","volume":"2","author":"Dietzschold","year":"2003","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"10.1016\/j.vaccine.2014.06.058_bib0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00705-010-0909-4","article-title":"Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice","volume":"156","author":"Huang","year":"2011","journal-title":"Arch Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2014.06.058_bib0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1096\/fj.09-138644","article-title":"Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB\/c mice","volume":"24","author":"Kaur","year":"2010","journal-title":"FASEB J"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2014.06.058_bib0045","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virol.2006.07.037","article-title":"A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice","volume":"356","author":"Li","year":"2006","journal-title":"Virology"},{"issue":"19","key":"10.1016\/j.vaccine.2014.06.058_bib0050","doi-asserted-by":"crossref","first-page":"10366","DOI":"10.1128\/JVI.01035-10","article-title":"Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets","volume":"84","author":"Bosch","year":"2010","journal-title":"J Virol"},{"issue":"6965","key":"10.1016\/j.vaccine.2014.06.058_bib0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"Pt 2","key":"10.1016\/j.vaccine.2014.06.058_bib0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1099\/0022-1317-70-2-291","article-title":"Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein","volume":"70","author":"Bunschoten","year":"1989","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2014.06.058_bib0065","series-title":"Laboratory techniques in rabies","article-title":"The NIH potency test","author":"Wilbur LAaA","year":"1996"},{"issue":"1","key":"10.1016\/j.vaccine.2014.06.058_bib0070","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","article-title":"Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody","volume":"212","author":"Cliquet","year":"1998","journal-title":"J Immunol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2014.06.058_bib0075","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1128\/JCM.43.6.2786-2792.2005","article-title":"Development of a real-time, TaqMan reverse transcription-PCR assay for detection and differentiation of lyssavirus genotypes 1, 5, and 6","volume":"43","author":"Wakeley","year":"2005","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2014.06.058_bib0080","doi-asserted-by":"crossref","first-page":"e1002682","DOI":"10.1371\/journal.ppat.1002682","article-title":"In vitro and in vivo isolation and characterization of Duvenhage virus","volume":"8","author":"Koraka","year":"2012","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.vaccine.2014.06.058_bib0085","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur behandlung kollektiver Reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Arch Exp Pathol Pharmakol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.06.058_bib0090","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1099\/0022-1317-64-4-843","article-title":"Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies","volume":"64","author":"Lafon","year":"1983","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2014.06.058_bib0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1084\/jem.20042060","article-title":"Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization","volume":"201","author":"Blink","year":"2005","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2014.06.058_bib0100","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/JVI.69.3.1895-1902.1995","article-title":"Bone marrow is a major site of long-term antibody production after acute viral infection","volume":"69","author":"Slifka","year":"1995","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2014.06.058_bib0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0264-410X(93)90379-C","article-title":"Oral vaccination of racoons (Procyon lotor) with baculovirus-expressed rabies virus glycoprotein","volume":"11","author":"Fu","year":"1993","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.06.058_bib0110","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0042-6822(89)90551-5","article-title":"Immunogenic and protective properties of rabies virus glycoprotein expressed by baculovirus vectors","volume":"173","author":"Prehaud","year":"1989","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.vaccine.2014.06.058_bib0115","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1128\/JVI.80.3.1414-1426.2006","article-title":"Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants","volume":"80","author":"Li","year":"2006","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2014.06.058_bib0120","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1084\/jem.20100025","article-title":"Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates","volume":"207","author":"Sundling","year":"2010","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.vaccine.2014.06.058_bib0125","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/JVI.75.3.1165-1171.2001","article-title":"Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers","volume":"75","author":"Yang","year":"2001","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2014.06.058_bib0130","doi-asserted-by":"crossref","first-page":"e41451","DOI":"10.1371\/journal.pone.0041451","article-title":"Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen","volume":"7","author":"Reimer","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.vaccine.2014.06.058_bib0135","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1586\/14760584.5.5.603","article-title":"Pandemic influenza vaccine development: time is of the essence","volume":"5","author":"Cox","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2014.06.058_bib0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/infdis\/jis330","article-title":"T-helper 1 cells elicited by H5N1 vaccination predict seroprotection","volume":"206","author":"Pedersen","year":"2012","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2014.06.058_bib0145","doi-asserted-by":"crossref","first-page":"e1002971","DOI":"10.1371\/journal.ppat.1002971","article-title":"Immune clearance of attenuated rabies virus results in neuronal survival with altered gene expression","volume":"8","author":"Gomme","year":"2012","journal-title":"PLoS Pathog"},{"issue":"7","key":"10.1016\/j.vaccine.2014.06.058_bib0150","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1128\/JVI.02052-09","article-title":"Vesicular stomatitis virus genomic RNA persists in vivo in the absence of viral replication","volume":"84","author":"Simon","year":"2010","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14008597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14008597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T07:12:21Z","timestamp":1597993941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14008597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":30,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0264410X14008597"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.06.058","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}